Stocks of CytomX Therapeutics Inc (NASDAQ:CTMX) traded higher last session on Wall Street, up 4.41% to $2.13.
CTMX stock price is now 126.47% away from the 50-day moving average and 111.91% away from the 200-day moving average. The market capitalization of the company currently stands at $335.57M.
With the price target maintained at $5, H.C. Wainwright recently Upgraded its rating from Neutral to Buy for CytomX Therapeutics Inc (NASDAQ: CTMX). , while ‘Wedbush’ rates the stock as ‘Outperform’
In other news, McCarthy Sean A., CEO sold 37,656 shares of the company’s stock on Mar 18 ’25. The stock was sold for $22,556 at an average price of $0.60. Upon completion of the transaction, the CEO now directly owns 995,195 shares in the company, valued at $2.12 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 18 ’25, Chief Financial Officer Ogden Christopher sold 8,551 shares of the business’s stock. A total of $5,122 was realized by selling the stock at an average price of $0.60. This leaves the insider owning 201,026 shares of the company worth $0.43 million. A total of 2.46% of the company’s stock is owned by insiders.
During the past 12 months, CytomX Therapeutics Inc has had a low of $0.40 and a high of $2.55. As of last week, the company has a debt-to-equity ratio of 0.33, a current ratio of 1.73, and a quick ratio of 1.73. The fifty day moving average price for CTMX is $0.94058 and a two-hundred day moving average price translates $1.00516 for the stock.
The latest earnings results from CytomX Therapeutics Inc (NASDAQ: CTMX) was released for 2025-03-31. The company reported revenue of $50.92 million for the quarter, compared to $41.46 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 22.8 percent.
